Search results
Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in TP53 Positive Patients...
NBC 17 Raleigh· 3 days agoThe Phase 3 SIERRA trial enrolled 153 patients ages 55 and above with active relapsed or refractory acute myeloid leukemia (r/r AML) and compared outcomes of patients receiving ...
Angle PLC Announces Study of Ovarian Cancer CTCs Using Parsortix
Digital Journal· 1 day agoINDEPENDENT STUDY OF OVARIAN CANCER CTCS HARVESTED BY THE PARSORTIX SYSTEM HIGHLIGHTS POTENTIAL TO PREDICT PROGRESSION FREE SURVIVAL FOR DRUG TRIALSThe study investigated ...
Ryvu Therapeutics First Quarter 2024 Financial Results and Corporate Update
WJTV Jackson· 3 days agoAs of May 9, 2024, Ryvu's cash position was $59.0M, inclusive of the first tranche of €8M in venture debt from the EIB, obtained in March. This cash position, and other secured funding sources ...
AP Investigation: In hundreds of deadly police encounters, officers broke multiple safety guidelines
Seattle Times· 3 days agoIn hundreds of deaths where police used force meant to stop someone without killing them, officers...
Review: PEOPLE, PLACES & THINGS, Trafalgar Theatre
Broadway World· 3 days agoIt’s nearly a decade since Denise Gough set the stage alight in Duncan MacMillan’s starkly raw study of addiction. She now reprises her Olivier and...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 2 days agoMoleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid Congress PR Newswire HOUSTON, May 16, 2024 HOUSTON, May 16, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or
US FDA approves expanded use of Bristol Myers' cancer cell therapy
Reuters· 2 days ago, opens new tab cancer cell therapy Breyanzi for the treatment of adults with a type of blood cancer...
Biotech Stock Roundup: NVAX, FULC Up on Deals With SNY, Updates From MRNA, BMY
Zacks via Yahoo Finance· 1 day agoThe FDA extended the review time for the above BLA... (lisocabtagene maraleucel; liso-cel). The...
FDA Broadens Breyanzi's Follicular Lymphoma Indication
Medscape· 2 days agoThe overall response rate to the CAR T therapy was 95.7% in phase 2 testing.
FDA Approves Tarlatamab for Extensive-Stage SCLC
Medscape· 2 days agoContinued approval of the first-in-class bispecific T-cell engager (BiTE) may depend on proof of clinical benefit.